Objective To investigate the clinical effect of preoperative
neoadjuvant chemotherapy by
thalidomide combined with
gefitinib for
non-small cell lung cancer (NSCLC)
patients and provide clinical basis for NSCLC
therapy.
Methods From 2011/1 to 2013/1,we collected 160 NSCLC cases in our
hospital and divided them into 2 groups randomly,80 cases in
control group and 80 cases in
observation group.The
patients in the
control group were treated with conventional surgical
treatment and
patients in the
observation group were treated with preoperative
neoadjuvant chemotherapy by
thalidomide combined with
gefitinib before
surgery.The clinical effects,the 6 months and 1 year
survival rates,and the
toxicity effects were observed,and the clinical effects and
survival rates between the 2 groups were compared.Results The
observation group had a
therapeutic efficiency ratio (TER) of 80.0% which was significantly higher than the
control group (50.0%),and the difference was statistically significant (P<0.05).The 6 months
survival rate and 1 year
survival rate were 97.5% and 92.5%,which were both significantly higher than those of
control group (87.5% and 77.5%),and all differences were statistically significant (P<0.05).The
toxicity effects of
observation group were lower.Conclusions Preoperative
neoadjuvant chemotherapy by
thalidomide combined with
gefitinib for NSCLC
therapy is effective and safe,which is worthy of study and further application in clinical
treatment..